SCHEMBL18189619

SCHEMBL18189619

Cc1cccc(-c2ccccc2F)c1-c1ccc2c(c1)CC(=O)N2

nearest known ligand 0.72

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ GRIA1 P42261 9/20 0.72
▸ CACNG8 Q8WXS5 3/20 0.72
▸ ALOX5AP P20292 1/20 0.49
▸ FEN1 P39748 1/20 0.49
▸ PGR P06401 4/20 0.48
▸ BRD4 O60885 1/20 0.47
▸ CREBBP Q92793 1/20 0.47
▸ PDE3B Q13370 1/20 0.45
▸ PDE3A Q14432 1/20 0.45
▸ CYP1A2 P05177 1/20 0.43
▸ CYP11B1 P15538 1/20 0.43
▸ CYP11B2 P19099 1/20 0.43
▸ CRBN Q96SW2 1/20 0.43
▸ PDE4A P27815 1/20 0.40
▸ PDE4B Q07343 1/20 0.40
▸ PDE4C Q08493 1/20 0.40
▸ PDE4D Q08499 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28203387 0.92 GRIA1 (0.70) GRIA1CACNG8ALOX5APFEN1PGR
SCHEMBL18189476 0.89 GRIA1 (0.82) GRIA1CACNG8ALOX5APFEN1PGR
SCHEMBL18189441 0.87 GRIA1 (0.74) GRIA1CACNG8ALOX5APFEN1PGR
SCHEMBL18189267 0.86 GRIA1 (0.78) GRIA1CACNG8ALOX5APFEN1PGR
SCHEMBL18189631 0.85 GRIA1 (1.00) GRIA1CACNG8PGRBRD4CREBBP
SCHEMBL24884440 0.83 GRIA1 (0.69) GRIA1CACNG8ALOX5APFEN1PGR
SCHEMBL18189405 0.83 GRIA1 (0.70) GRIA1CACNG8ALOX5APFEN1PGR
SCHEMBL18189580 0.81 GRIA1 (0.49) GRIA1CACNG8ALOX5APFEN1PGR
SCHEMBL10714302 0.81 GRIA1 (1.00) GRIA1CACNG8ALOX5APFEN1PGR
SCHEMBL21533151 0.79 GRIA1 (0.69) GRIA1CACNG8PGRBRD4CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107750250-B Indolone compounds and their use as AMPA receptor modulators 詹森药业有限公司 2021-09-07 — — CN claimed
US-10604484-B2 Indolone compounds and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2020-03-31 — — US claimed
EP-3288935-B1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-10-30 — — EP claimed
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 — — US claimed
EP-3288935-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2018-03-07 — — EP claimed
WO-2016176463-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2016-11-03 — — WO claimed
CN-107750250-B Indolone compounds and their use as AMPA receptor modulators 詹森药业有限公司 2021-09-07 — — CN disclosed
US-10604484-B2 Indolone compounds and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2020-03-31 — — US disclosed
US-10604484-B2 Indolone compounds and their use as AMPA receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2020-03-31 — — US disclosed
EP-3288935-B1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-10-30 — — EP disclosed
EP-3288935-B1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2019-10-30 — — EP disclosed
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 — — US disclosed
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 — — US disclosed
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-03 — — US disclosed
EP-3288935-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2018-03-07 — — EP disclosed
WO-2016176463-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2016-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10604484-B2 Indolone compounds and their use as AMPA receptor modulators GRIN3A, GRIN1, GRIN2B GRIA1 23/4885CACNG8 317/4885ALOX5AP 1124/4885
US-20180118683-A1 INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS GRIN3A, GRIN1, GRIN2B GRIA1 23/4885CACNG8 317/4885ALOX5AP 1124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback